Initial chemotherapy and low-dose radiation in limited fields in childhood Hodgkin's disease: results of a joint cooperative study by the French society of pediatric oncology (SFOP) and hôpital Saint-Louis, Paris

Dionet, C; Oberlin, Odile; Habrand, Jean‐Louis; Vilcoq, Jacques R.; Madelain, M; Dutou, L; Bey, P.; Lefur, R.; Thierry, P; Floch, O. Le; Sarrazin, D.

doi:10.1016/s0360-3016(98)90013-x

Cited by 30 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, and the most obvious, is that health care in these countries is worse and patients look for medical care only when the disease is already extensive. This does not seem to be the only explanation in our series, since we had 50% of advanced stages, which is higher than the French study [19], but is similar to the findings from Stanford [18]. This group, however, presented only 18% .…”

Section: Discussionsupporting

confidence: 65%

Childhood Hodgkin's disease in Campinas, Brazil

Faria

Vassallo

Cosset

et al. 1996

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 65%

Childhood Hodgkin's disease in Campinas, Brazil

Faria

Vassallo

Cosset

et al. 1996

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

“…They remain at risk of dying of thryoid carcinoma many years later [2]. The high disease control rates presented here are similar to those of other investigators who have evaluated bimodal treatment in early and/or late stages of Hodgkin's disease in children [3-111, although the 5 year RFS of 60% for CS 4 patients is in the lower range of reported results for MOPP, ABVD, or combinations of these agents, 54-77% [6][7][8]10,11]. The systemic sites involved in the 15 CS 4 patients were lung, 9 patients (3 relapsed); liver, 5 patients (1 relapsed); and bone and liver, 1 patient who relapsed.…”

Section: Discussionsupporting

confidence: 82%

Hodgkin's disease in children: Treatment with MOPP and low‐dose, extended field irradiation without laparotomy late results and toxicity

Jenkin

Doyle

Berry

et al. 1990

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

The 10 year results of a trial of bimodal treatment of Hodgkin's disease in children with 6 cycles of MOPP and low-dose extended field irradiation, without staging laparotomy, were for 57 children in all stages as follows: survival 85%, relapse-free survival 80%, and survival-free of second relapse 86%. There were three fatal toxic events, two due to viral infection and one to a second malignant tumor (NHL). Three other patients developed a second malignant tumour, and one developed a thyroid adenoma. No patient developed acute leukemia. These results are compared with the results of treatment of surgically staged children by extended field irradiation alone, with bimodal treatment reserved for relapse or advanced disease at diagnosis. Initial bimodal treatment improved the overall 10 year survival free from a second relapse rate by 20% (86% vs. 66%). No major difference in treatment toxicity between these two groups has emerged during the first 10 years of follow-up. We conclude that, except for favourable CS-1 presentations, children with Hodgkin's disease confined to the lymphatic system should be given bimodal treatment, but that the least morbid effective combination remains to be determined.

show abstract

“…In children with stage IV HD given combined treatment, poorer therapeutic results were achieved compared to patients with other HD stages (Table III) [15,16,19,21,32]. As was demonstrated for a large group of adolescents and adults, patients with lymphocyte depletion type at stage III, and especially at stage IV, showed worse therapeutic results [33].…”

Section: Discussionmentioning

confidence: 99%

“…Hunger et al [15] EFS 69% (10) I-IV EFS 93% (10) Jenkin et al [16] RFS 65% (10) I-IV RFS 86% (10) Oberlin et al [19] RFS 63% (6) I-II RFS 89% (6) III RFS 82% (6) Vecchi et al [21] FFP 41% (7) I FFP 92.7% (7) II FFP 84.9% (7) III FFP 81.5% (7) Dionet et al [32] RFS 54% (4) I-IV RFS 86% (4) *RFS, relapse-free survival; EFS, event-free survival; FFP, freedom from progression. …”

Section: Authorsmentioning

confidence: 99%